Semaglutide Slashes Inflammation Marker by 37.8%, Potentially Explaining Heart Benefits
New analysis of the SELECT trial shows semaglutide significantly reduced the inflammatory marker hsCRP by 37.8% in patients with heart disease and obesity. This reduction, observed early and even with minimal weight loss, suggests inflammation may partly mediate the drug's cardiovascular benefits, though causality isn't proven.